| Home : CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia |
|
Dec 12
2019 |
CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia |
|
SUZHOU, China, Dec. 12, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the Company has recently received the approval from the Human Research Ethics Committee (HREC) in Australia, and the acknowledgement from Australia's... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/cstone-completes-registration-filing-for-the-phase-i-trial-of-its-tumor-immune-microenvironment-modulator-cs3005-to-enable-study-initiation-in-australia-300973803.html |
| |
|
Related News
|
» Alfred Landecker Foundation Pledges 5 Million Euros To The Claims Conference To Support Holocaust Survivors
» Nordic Nanovector Provides Update on LYMRIT 37-05 Phase 1 DLBCL Trial
|
